{"schema":"hottub-news/story/v1","story":"st_ep77polfk6bbuteyhswa","title":"Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL","title_en":null,"outlets":1,"brief":null,"page":"https://hottub.news/stories/lillys-jaypirca-pirtobrutinib-the-first-and-only-approved-non-covalent-ep77polfk6","count":1,"items":[{"id":"n_ep77polfk6bbuteyhswa","seq":1419182,"kind":"article","title":"Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL","url":"http://www.prnewswire.com/news-releases/lillys-jaypirca-pirtobrutinib-the-first-and-only-approved-non-covalent-btk-inhibitor-receives-expanded-indication-from-us-fda-for-certain-patients-with-previously-untreated-cllsll-302897416.html","published":"2026-10-02T19:30:00Z","seen":"2026-10-02T19:47:13Z","lang":"en","source":{"id":"prnewswire.com","name":"prnewswire.com","domain":"prnewswire.com","outlet":{"wikidata":"Q376399","name":"PR Newswire","type":"other","country":"US","designations":["business","information resource"]}},"via":"gdelt-gkg-english","topics":["economy","health","science","education"],"authors":["Eli Lilly","Company"],"entities":[{"id":"Q1073913","name":"Lilly","type":"org"},{"id":"Q116622551","name":"pirtobrutinib","type":"other"},{"id":"Q18557229","name":"chronic lymphocytic leukemia and small lymphocytic lymphoma","type":"other"}],"story":"st_ep77polfk6bbuteyhswa","category":"health","category_p":0.6700000166893005,"sentiment":"neutral","tone":-0.47999998927116394,"political":0.12999999523162842}]}